Kidney Research and Clinical Practice

The pathophysiological significance between autosomal dominant polycystic kidney disease and neutrophil gelatinase-associated lipocalin: Pallavi Devapatla, Wen-Yih Jeng, Wen-Tai Chiu, Hsiu Mei Hsieh-Li; Kidney Res Clin Pract. 2025;44(2):238-248. Published online March 12, 2025; DOI: https://doi.org/10.23876/j.krcp.23.339; Full text PubReader ePub PDF

Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report: Hayne Cho Park, Yong Chul Kim, Hyunsuk Kim et al.; Received March 10, 2024 Accepted June 7, 2024 Published online September 11, 2024; [Epub ahead of print]; Full text PubReader ePub PDF Supplementary Material

Baseline characteristics of the Korean genetic cohort of inherited cystic kidney disease: Jeong Min Cho, Hayne Cho Park, Jin Woo Lee et al.; Kidney Res Clin Pract. 2023;42(5):617-627. Published online September 27, 2023; DOI: https://doi.org/10.23876/j.krcp.23.097
Web of Science 1 Cited By 1; Full text PubReader ePub PDF Supplementary Material

Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period: Hyuk Huh, Yong Soo Kim, Wookyung Chung et al.; Kidney Res Clin Pract. 2023;42(2):216-228. Published online January 13, 2023; DOI: https://doi.org/10.23876/j.krcp.22.024
Web of Science 2 Cited By 2; Full text PubReader ePub PDF Supplementary Material

Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression: Hyunsuk Kim, Jinmo Sung, Ju Young Bae, Poongyeon Lee, Yun Kyu Oh, Hyunho Kim; Kidney Res Clin Pract. 2022;41(6):730-740. Published online June 20, 2022; DOI: https://doi.org/10.23876/j.krcp.21.303
Web of Science 8 Cited By 10; Full text PubReader ePub PDF

Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options: Yeshwanter Radhakrishnan, Parikshit Duriseti, Fouad T. Chebib; Kidney Res Clin Pract. 2022;41(4):422-431. Published online March 29, 2022; DOI: https://doi.org/10.23876/j.krcp.21.309
Web of Science 9 Cited By 11; Full text PubReader ePub PDF

Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study: Hayne Cho Park, Yeji Hong, Jeong-Heum Yeon et al.; Kidney Res Clin Pract. 2022;41(4):432-441. Published online March 3, 2022; DOI: https://doi.org/10.23876/j.krcp.21.261
Web of Science 6 Cited By 8; Full text PubReader ePub PDF Supplementary Material

Comparison of chronic kidney disease trial designs and analysis strategies: John Lawrence; Kidney Res Clin Pract. 2021;40(1):62-68. Published online March 5, 2021; DOI: https://doi.org/10.23876/j.krcp.20.104
Web of Science 1 Cited By 1; Full text PubReader ePub PDF Supplementary Material

PKD2 mutation in an Iranian autosomal dominant polycystic kidney disease family with misleading linkage analysis data^☆: Mona Entezam, Mohammad Reza Khatami, Fereshteh Saddadi, Mohsen Ayati, Jamshid Roozbeh, Mohammad Keramatipour; Kidney Res Clin Pract. 2016;35(2):96-101. Published online February 27, 2016; DOI: https://doi.org/10.1016/j.krcp.2016.02.003
Web of Science 2 Cited By 2; Full text PubReader PDF

Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease: Seung Hun Lee, Stefan Somlo; Kidney Res Clin Pract. 2014;33(2):73-78. Published online June 14, 2014; DOI: https://doi.org/10.1016/j.krcp.2014.05.002
Web of Science 37 Cited By 33; Full text PubReader PDF

Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside: Hyun-Jung Kim, Charles L. Edelstein; Kidney Res Clin Pract. 2012;31(3):132-138. Published online August 10, 2012; DOI: https://doi.org/10.1016/j.krcp.2012.07.002
Cited By 17; Full text PubReader PDF

Laparoscopic biopsy-proven lupus nephritis in autosomal dominant polycystic kidney disease: Ji In Park, Hajeong Lee, Jung Nam An, Ho Jun Chin, Suhnggwon Kim; Kidney Res Clin Pract. 2012;31(3):192-195. Published online June 26, 2012; DOI: https://doi.org/10.1016/j.krcp.2012.06.002
Cited By 3; Full text PubReader PDF

The Usefulness of Urinary Angiotensinogen as a Biomarker of Renal Progression in Autosomal Dominant Polycystic Kidney Disease: Hayne Cho Park, M.D. Jin Ho Hwang, M.D. Seon ha Baek, M.D. Mi Yeun Han, M.D. Yu Kyoung Yun, B.S. Myeong-Ok Yoon, B.S. Kook-Hwan Oh, M.D. Ja Ryong Koo, M.D. Hyung Jik Kim, M.D. Jung Woo Noh, M.D. Kyu Beck Lee, M.D. Woo Kyung Chung,; Korean J Nephrol. 2011;30(5):506-515.; PDF

Pathogenesis and New Treatment of Autosomal Dominant Polycystic Kidney Disease: Soo Wan Kim, M.D.; Korean J Nephrol. 2011;30(3):231-238.; PDF

A Case of Spontaneous Subdural Hematoma in a Patient with Autosomal Dominant Polycystic Kidney Disease: Won Ik Jang, M.D., Young Rok Ham, M.D., Ji Yoon Jung, M.D., Dong Suk Chang, M.D., Sarah Chung, M.D., Dae Eun Choi, M.D., Ki Ryang Na, M.D., Kang Wook Lee, M.D. and Young Tai Shin, M.D.; Korean J Nephrol. 2010;29(6):802-806.; PDF

4,482	Personalized nutritional management in the transition from non-dialysis dependent chronic kidney disease to dialysis
4,109	Longitudinal progression trajectory of estimated glomerular filtration rate in children with chronic kidney disease: results from the KNOW-Ped CKD (KoreaN cohort study for Outcomes in patients With Pediatric Chronic Kidney Disease)
14,165	How should we treat acute kidney injury caused by renal congestion?
5,044	Artificial intelligence and machine learning’s role in sepsis-associated acute kidney injury
2,527	Management of high-flow arteriovenous access

Cited By 24	Uremic pruritus: pathophysiology, clinical presentation, and treatments
Cited By 19	Deep learning predicts the differentiation of kidney organoids derived from human induced pluripotent stem cells
Cited By 16	Body water percentage from childhood to old age
Cited By 16	Acute kidney disease: an overview of the epidemiology, pathophysiology, and management
Cited By 15	The flavonoid fisetin ameliorates renal fibrosis by inhibiting SMAD3 phosphorylation, oxidative damage, and inflammation in ureteral obstructed kidney in mice

Search